Highlights AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:55 10/04/2026 BST			5-day change	1st Jan Change
207.94 ^USD	-2.10%		-0.43%	-8.99%

04-10	AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says	MT
04-10	Guggenheim Adjusts Price Target on AbbVie to $249 From $242, Maintains Buy Rating	MT

Highlights

04-10	AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says	MT
04-09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
04-09	Wall Street Rethinks the Rally
04-08	AbbVie files lawsuit to address 'outdated' drug discount eligibility program	RE
04-08	AbbVie Sues to Narrow Definition of Eligible Patients in US Drug Discount Program	MT
04-08	AbbVie Sues to Narrow Definition of Eligible Patients in US Drug Discount Program	MT
04-08	AbbVie Sues Trump Administration to Narrow Eligible Patient Definition in Discount Drug Program, Axios Reports	MT
04-08	AbbVie files lawsuit to address 340B program guidance	RE
04-02	US Set to Impose 100% Tariffs on Some Drug Imports	MT
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-28	Incyte's skin disease drug shows long-term symptom relief in late-stage trials	RE
03-27	AbbVie Announces to Present New Research Across its Dermatology Portfolio at 2026 American Academy of Dermatology Annual Meeting	CI
03-25	Merck braces for Keytruda patent loss with $6.7 billion Terns bet	RE
03-20	US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings	RE
03-18	US STOCKS-Wall Street remains lower after Fed keeps rates unchanged	RE
03-17	Big drugmakers must face US overcharge claims on medications for low-income patients	RE
03-17	Alloy Therapeutics, Inc. Enters into Agreement to Advance Novel Antibody Discovery Platform	CI
03-17	US FDA declines to approve Aldeyra's eye disorder drug, shares slump	RE
03-17	US FDA declines to approve Aldeyra's drug for eye disorder	RE
03-09	AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 million - SEC filing	RE
03-09	AbbVie Announces Positive Topline Results From A Phase 1 Multiple Ascending Dose Study of ABBV-295	CI
03-09	Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB…
03-05	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI